Attendees of the $349 “ Don’t Die Summit ” at the west side’s Javits Center tried red light therapy, discovered their ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

It’s the smallest Hall of Fame class in 20 years. Not making the cut: Eli Manning. The former New York Giants quarterback, a two-time Super Bowl MVP, was bypassed by the 49-member selection ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.